- Home
- ESPR
as 10-08-2025 11:18am EST
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | ANN ARBOR |
| Market Cap: | 534.3M | IPO Year: | 2013 |
| Target Price: | $6.50 | AVG Volume (30 days): | 7.0M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.69 - $3.94 | Next Earning Date: | 11-06-2025 |
| Revenue: | $268,125,000 | Revenue Growth: | -3.48% |
| Revenue Growth (this year): | 13.05% | Revenue Growth (next year): | -7.27% |
Stock Insider Trading Activity of Esperion Therapeutics Inc. (ESPR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Looker Benjamin | ESPR | General Counsel | Sep 17 '25 | Sell | $2.80 | 6,267 | $17,572.67 | 393,670 | |
| Koenig Sheldon L. | ESPR | President and CEO | Sep 17 '25 | Sell | $2.79 | 28,427 | $79,254.48 | 1,518,831 | |
| Halladay Benjamin | ESPR | Chief Financial Officer | Sep 17 '25 | Sell | $2.81 | 7,046 | $19,785.17 | 474,862 |
Latest Esperion Therapeutics Inc. News
ESPR Breaking Stock News: Dive into ESPR Ticker-Specific Updates for Smart Investing
Zacks
4 months ago
Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?
GlobeNewswire
4 months ago
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
GlobeNewswire
5 months ago
Esperion to Participate in Upcoming June Investor Conferences
MT Newswires
5 months ago
Esperion Therapeutics, Micro Labs Settle Generic Nexletol Patent Dispute
GlobeNewswire
5 months ago
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
Pharmaceutical Technology
5 months ago
HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines
GlobeNewswire
5 months ago
Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference
GlobeNewswire
5 months ago
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Compare ESPR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ESPR Esperion Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.